Quest Diagnostics Incorporated
NYSE•DGX
CEO: Mr. James E. Davis
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 1996-12-17
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Contact Information
Market Cap
$21.89B
P/E (TTM)
22.0
29.6
Dividend Yield
1.7%
52W High
$213.50
52W Low
$157.20
52W Range
Rank24Top 10.8%
5.7
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$2.81B+0.00%
4-Quarter Trend
EPS
$2.21+0.00%
4-Quarter Trend
FCF
$307.00M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Strong Revenue and Income Growth Total net revenues reached $11.04B USD, growing 11.8%. Net income attributable to Quest Diagnostics was $992M USD, up 13.9%.
Advanced Diagnostics Revenue Milestone Advanced Diagnostics offerings generated over $1B USD in 2025 revenues, achieving double-digit growth across key clinical areas.
Operating Efficiency Improvements Operating income grew 15.6% to $1.56B USD, supported by Invigorate program savings offsetting inflationary pressures.
Capital Return Commitment Board authorized $1B increase to share repurchase program; quarterly dividend raised 7.5% to $0.86 per share.
Risk Factors
Reimbursement Rate Uncertainty Ongoing PAMA uncertainty and government payer efforts to reduce utilization and reimbursement pose material risks to revenue stability.
Competitive Testing Internalization Competition intensifies from hospital-affiliated labs and providers internalizing testing, potentially reducing outreach volume and pricing power.
Inflationary Cost Pressures Rising costs for labor, benefits, testing equipment, and supplies pressure margins despite Invigorate cost savings efforts.
Cybersecurity and IT System Risks Reliance on IT systems exposes operations to cyberattacks, data breaches, and potential disruption from Project Nova modernization.
Outlook
Modernizing Order to Cash Committed to multi-year Project Nova to modernize IT infrastructure, expecting completion in 2031 to 2032 for streamlined operations.
Strategic Capital Investment Focus Estimate $550M capital expenditure in 2026 for lab equipment, automation, and technology supporting diagnostic offerings growth.
Continued Advanced Testing Focus Strategy emphasizes growing Advanced Diagnostics, including oncology monitoring via Haystack Oncology MRD test commercialization.
Maintaining Strong Liquidity Expect sufficient cash flow and $1.3B borrowing capacity to fund operations, acquisitions, and debt obligations through 2026.
Peer Comparison
Revenue (TTM)
$21.31B
$13.95B
$11.04B
Gross Margin (Latest Quarter)
92.3%
90.9%
86.9%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| NTRA | $29.66B | -137.5 | -15.3% | 8.5% |
| MTD | $25.81B | 29.8 | -487.2% | 63.1% |
| BIIB | $25.77B | 19.9 | 7.3% | 23.6% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1.9%
Moderate Growth
4Q Net Income CAGR
3.7%
Profitability Slowly Improving
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:Apr 20, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data